OBT076 Phase 1b Trial initiation: Oxford BioTherapeutics, in collaboration with GORTEC, has initiated a Phase 1b trial for OBT076, an ADC targeting the CD205 receptor in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck

Novel treatment for rare cancer type: ACC is a rare and aggressive cancer type lacking established treatments. OBT076’s dual mechanism of action, targeting the CD205 receptor in tumor and immune cells, presents a promising approach to address the high unmet need in ACC and other solid tumors

International collaboration and research consortium: The Phase 1b trial, sponsored by GORTEC, involves 15 study sites across France, Belgium, and Switzerland, the trial aims to assess OBT076 both as a monotherapy and in combination with balstilimab, a PD-1 blocking antibody

Ongoing clinical trials and positive preliminary data: OBT076 is concurrently being evaluated in Phase 1 clinical trials for various advanced solid tumor indications in the US and Europe. Preliminary data suggests clinical activity as a single agent and in combination with checkpoint inhibitors, demonstrating its potential in addressing advanced and refractory tumors